HIV Protease Inhibitor

LY-326188 is a HIV-1 protease inhibitor, with an IC₅₀ of 0.42 nM. LY326188 exhibits potent protection of HIV-1 infected cells.

Mozenavir dimethanesulfonate (DMP-450 dimethanesulfonate) is an orally active cyclic urea HIV-1 protease inhibitor with an IC₅₀ of 76 nM. Mozenavir dimethanesulfonate inhibits replication by targeting viral protease, blocks viral polyprotein processing, and induces the production of core-uncondensed, immature, non-infectious viral particles in chronically infected cells. Mozenavir dimethanesulfonate is applicable to research related to HIV infection.

SRI-32743 is an allosteric human dopamine transporter (hDAT) modulator (IC₅₀=9.86 μM). SRI-32743 is promising for research of HIV-Tat-induced neurotoxicity.

HIV-1 protease-IN-15 (Compound 27) is an orally active and selective inhibitor targeting HIV-1 protease with a pIC₅₀ value of 9.347. HIV-1 protease-IN-15 inhibits HIV protein maturation, blocks viral replication. HIV-1 protease-IN-15 is promising for research of HIV-1 infection.

Lasinavir (CGP 61755) is a selective HIV-1 protease inhibitor with an IC₅₀ of 1 nM. Lopinavir can be used in HIV-1 infection studies.

Atazanavir-d₂₄ (BMS-232632-d₂₄) is deuterium labeled Atazanavir. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.

L-689502 is a potent inhibitor of HIV-l protease with an IC₅₀ of 1 nM.